Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib ± Pembrolizumab as Neoadjuvant Therapy for HRD-Positive Advanced Ovarian Cancer (OLAPem)
jRCT2080225217Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by National Cancer Center Hospital East. Started Jun 2020; status: completed.
02
Drugs
olaparibpembrolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080225217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225217.